Medical team

康智雄


現任

  • 高雄長庚紀念醫院助理教授級主治醫師

  • 高雄長庚紀念醫院泌尿腫瘤團隊副召集人


  • 台灣泌尿腫瘤醫學會理事


  • 中華民國癌症醫學會腫瘤外科指導老師


  • 衛福部醫療爭議委員會審議委員


  • 台灣泌尿科醫學會會員


  • 台灣外科醫學會會員

學歷

  • 國立陽明醫學院醫學士

  • 國立中山大學生物醫學科學研究所碩士

經歷

  • 高雄市立民生醫院兼任主治醫師

  • 雲林長庚紀念醫院主治醫師

  • 國科會研究計畫主持人

  • 國健署泌尿腫瘤核心測量指標計畫主持人

  • 健保署高屏分局審查委員

  • 台灣泌尿腫瘤醫學會監事

專長

  • 泌尿道腫瘤 泌尿道結石 膀胱輸尿管重建 泌尿內視鏡 
    腹腔鏡 疝氣 攝護腺雷射 生殖器與結紮手術

論文發表:

  1. Kang CH, Yu TJ*, Hsieh HH, Yang JW, Shu K, Huang CC, Chiang PH, and Shiue YL. The development of bladder tumors and contralateral upper tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003/Feb.; 98: 1620-1626 (SCI; IF=4.582; 20/114)
  2. Kang CH, Yu TJ*, Hsieh HH, Yang JW, Shu K and Shiue YL. Synchronous bilateral primary transitional cell carcinoma of the upper urinary tract: Ten cases with more than five-years of follow-up. Urology 2004/Mar; 63:380-382 (SCI; IF=2.139; 20/50)
  3. Kang CH, Chiang PH*, Huang SC. Correlation of COX-2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts. Urology 2008/Jan.;72: 153-7(SCI; IF=2.139; 20/50)
  4. The clinical characteristics of silmultaneous and subsequent transitional cell carcinomasof the upper urinary tracts. 碩士論文
  5. Luo HL, Kang CH, Chiang PH*. Gasless Hand Assisted Retroperitoneoscopic Nephroureterectomy. Journal of Endourology 2009;23:69-74 (SCI; IF = 1.930; 30/57)( SCI; IF=1.536; 26/50)
  6. Chen CH, Kang CH, Chiang PH: Intra-arterial Infusion of Chemotherapy in the Treatment of Penile Cancer. Jpn J Clin Oncol 2009;39:825-828 (SCI; IF=1.405; 118/141)
  7. Kang CH, Chien-Hsu Chen, Chiang PH: Primary Urothelial Carcinoma of the Upper Urinary Tract in Dialysis Patients with 5-year Follow-up. Jpn J Clin Oncol 2009;40:241-246 (SCI; IF=1.405; 118/141)
  8. Chiang PH, Chen CH, Kang CH, Chuang YC. GreenLight HPS laser 120-W versus diode laser 200-W vaporization of the prostate: comparative clinical experience. Lasers Surg Med. 2010 Sep;42(7):624-9
  9. Chiang PH1, Luo HL, Chen YT, Kang CH, Chuang YC, Lee WC. Is hand-assisted retroperitoneoscopic nephroureterectomy better than transurethral bladder cuff incision-assisted nephroureterectomy? J Endourol. 2011 Aug;25(8):1307-13
  10. Luo HL, Fang FM, Kang CH, Chuang YC, Chiang PH. Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate? Int Urol Nephrol. 2013 Feb;45(1):113-9.
  11. Chen CH, Chiang PH, Lee WC, Chuang YC, Kang CH, Hsu CC, Lee WC, Chen YT, Cheng YT. High-intensity diode laser in combination with bipolar transurethral resection of the prostate: a new strategy for the treatment of large prostates (>80 ml). Lasers Surg Med. 2012 Nov;44(9):699-704
  12. Luo HL, Kang CH, Chen YT, Chuang YC, Lee WC, Cheng YT, Chiang PH. Diagnostic ureteroscopy independently correlates with intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Ann Surg Oncol. 2013 Sep;20(9):3121-6
  13. Luo HL, Kang CH, Chen YT, Chuang YC, Lee WC, Cheng YT, Chiang PH. Severity of hydronephrosis correlates with tumour invasiveness and urinary bladder recurrence of ureteric cancer. BJU Int. 2013 Aug;112(4):489-94
  14. Luo HL, Chen YT, Chuang YC, Cheng YT, Lee WC, Kang CH, Chiang PH. Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome. BJU Int. 2014 May;113(5b):E144-9
  15. Luo HL, Kang CH, Chen YT, Chuang YC, Cheng YT, Lee WC, Chiang PH. Oncological impact of endoscopic bladder cuff management during nephroureterectomy varies according to upper urinary tract tumor location. Int J Urol. 2014 Apr;21(4):366-9
  16. Lin-Nei Hsu, Po-Hui Chiang, Chih-Hsiung Kang. Emphysematous prostatic abscess: Rare case and systematic review. Journal of the Formosan Medical Association. 2015, 114(3); 292–293
  17. Li CE, Chien CS, Chuang YC, Chang YI, Tang HP,, Kang CH. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. Int Urol Nephrol. 2016.
  18. Shen YC, Kang CH, Chiang PH.Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer. Kaohsiung J Med Sci. 2016.
  19. Shen YC, Chiang PH, Luo HL, Chuang YC, Chen YT, Kang CH, Hsu CC, Lee WC, Cheng YT. Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer Kaohsiung J Med Sci. 2016.
  20. Huang GL, Kang CH, Lee WC, Chiang PH. Comparisons of cancer detection rate and complications between transrectal and transperineal prostate biopsy approaches - a single center preliminary study. BMC Urol. 2019;19(1):101.
  21. 21.Su, Y. L., Luo, H. L., Huang, C. C., Liu, T. T., Huang, E. Y., Sung, M. T., Lin, J. J., Chiang, P. H., Chen, Y. T., Kang, C. H., & Cheng, Y. T.Galectin-1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and Survival. Cells, 9(4), 806,2020
  22. 22.Luo, H. L., Ohyama, C., Hatakeyama, S., Wang, H. J., Yoneyama, T., Yang, W. C., Chuang, Y. C., Chen, Y. T., Lee, W. C., Cheng, Y. T., Kang, C. H., & Chiang, P. H.  Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan-Japan UTUC Collaboration Cohort. International journal of urology : official journal of the Japanese Urological Association, 27(4), 327–332,2020


Top